Format

Send to

Choose Destination
Expert Rev Clin Immunol. 2010 Sep;6(5):713-20. doi: 10.1586/eci.10.67.

RAPID and FAST4WARD trials: certolizumab pegol for rheumatoid arthritis.

Author information

1
Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, AZ Maastricht, The Netherlands.

Abstract

In the last decade, biological therapies have dramatically changed the treatment for rheumatoid arthritis (RA) in such a way that remission is currently an achievable goal. The armamentarium of therapeutic options for RA has recently been enriched with another approved anti-TNF-alpha agent, certolizumab pegol (CZP). This article reviews the trials conducted with CZP in RA, the Rheumatoid Arthritis PreventIon of structural Damage (RAPID 1 and 2) and the EFficAcy and Safety of cerTolizumab pegol - 4 Weekly dosAge in RheumatoiD arthritis (FAST4WARD). These trials have demonstrated that this new biological agent significantly improves the clinical signs and symptoms of RA, inhibits progression of structural damage, and improves physical function and quality of life in patients with active RA who have failed treatment with methotrexate. The safety profile of CZP is acceptable and similar to that of other anti-TNF-alpha agents.

PMID:
20828279
DOI:
10.1586/eci.10.67
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center